Compare VICI Properties Inc (VICI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VICI Properties Inc vs State Street SPDR S&P Biotech ETF — how do they compare? VICI Properties Inc trades at $22.9 (market cap $25.09B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: VICI Properties Inc is far larger — about 2.5× State Street SPDR S&P Biotech ETF's market cap, and VICI Properties Inc pays a 8.07% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VICI Properties Inc for 42 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| VICI | XBI | |
|---|---|---|
Market Cap | $25.09B | $10.11B |
Volume | 17,066,337 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $31.42 | $169.55 |
52-Week Low | $22.53 | $104.99 |
Typical Hold Time | 42 Days | 37 Days |
Enterprise Value | $42.65B | — |
Dividend Yield | 8.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VICI Properties trades at $22.64, down 0.4% on the day, with a bearish technical outlook despite strong fundamentals. The REIT maintains exceptional profitability with 67.5% net margins and trades at attractive valuations (P/E 8.83, P/B 0.86). Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing, while the company continues expanding its tenant base through new lease agreements.
Wall Street remains bullish with 75% buy ratings and a $28.90 consensus target, representing 28% upside. Key risks include tenant concentration and rising interest rates, but the 7.8% dividend yield appears well-covered by strong cash flows. The current discount to NAV presents a compelling opportunity for income-focused investors.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
